Atlas Trials

Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia

Clinical trial NCT06772168 · RECRUITING

Trial details

NCT number
NCT06772168
Sponsor
CMG Pharmaceutical Co. Ltd
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
DyslipidemiaType 2 Diabetes
Start date
2024-04-19
Primary completion
2026-11-04
Enrollment
240

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.